BACKGROUND/MOTIVATION FOR THE STUDY {#sec1}
===================================

Low maximum oxygen uptake (V̇O~2max~) holds stronger mortality risk than other established variables such as smoking, obesity or diabetes. Positive adaptation in V̇O~2max~ following increased physical activity is a key inherited trait promoting survival. Plasticity in skeletal muscle oxidative capacity plays a major role in mediating this response ([@B3]). The HERITAGE study of 99 families that completed a 20 wk endurance training program identified \~50% heritability of V̇O~2max~ plasticity ([@B2]). Later, Timmons et al. ([@B5]) identified in muscle biopsies an mRNA expression-based molecular classifier of 29 genes predicting the training response and which were associated with 11 single nucleotide polymorphisms (SNPs) in the HERITAGE cohort. Approximately half of the genetic variance for V̇O~2max~ gained by exercise training was accounted for by these 11 SNPs.

Chronic obstructive pulmonary disease (COPD) is characterized by dyspnea, chronic inactivity, and negative muscle adaptations: major among these is loss of muscle oxidative capacity. Detrimental peripheral adaptations increase ventilatory demand during activities of daily living and are associated with reduced quality of life, morbidity, and mortality in COPD. While genomic and epigenomic variations in oxidative phosphorylation genes have been studied widely in chronic diseases, genetic association studies to explain low muscle oxidative capacity in humans have not. We therefore determined whether the 11 SNPs associated with muscle plasticity in healthy Caucasians were associated with variability in muscle oxidative capacity in non-Hispanic White (NHW) and African American (AA) smokers with and without COPD. Identifying new genetic loci associated muscle adaptations in COPD could potentially identify patients who may benefit most from pulmonary rehabilitation.

PHENOTYPE {#sec2}
=========

 {#sec2-1}

### Cohort details. {#sec2-1-1}

Participants were NHW (*n* = 84) and AA (*n* = 68) aged 45--80 yr with a \>10 pack-year smoking history from the COPDGene population cohort study ([@B4]). Exclusion criteria included non-COPD respiratory disorders, known or suspected lung cancer or other cancer, lung volume reduction, pregnancy, radiation therapy to the chest, chest or abdominal surgery (past 3 mo), heart attack (past 3 mo), hospitalization (past month). The 243 participants gave written informed consent to participate in the COPDGene Muscle Health ancillary study at LABioMed/Harbor-UCLA (Appendix 1, Supplemental Fig. S1). (The online version of this article contains supplemental material.) The primary trait of gastrocnemius oxidative capacity was determined from the muscle V̇O~2~ recovery rate constant (*k*) using near-infrared spectroscopy ([@B1]). Physical activity (steps/day) was assessed during the following 7 days by triaxial accelerometry (DynaPort MoveMonitor, McRoberts). Complete data from 84 COPD (66 ± 9 yr) and 68 smokers with normal spirometry (61 ± 9 yr) were used for final analyses (Appendix 2, Supplemental Table S1). Additional details are provided in Appendix 3.

### Type of study. {#sec2-1-2}

Candidate SNP study.

### Details of the SNP(s) studied. {#sec2-1-3}

Candidate SNPs were identified from Timmons et al. ([@B5]) representing 11 different genetic loci (see Appendix 3, Supplemental Table S1 for complete list). Genotyping for the COPDGene study was performed on the Illumina Human Omni-1 Quad array with imputation using the Haplotype Reference Consortium on the Michigan Imputation Server. Quality control details of the COPDGene genotyping data are given in Appendix 2, Supplemental Table S2. Four of the investigated SNPs were imputed: [rs3770991](https://www.ncbi.nlm.nih.gov/snp/3770991) within NRP2; [rs4257918](https://www.ncbi.nlm.nih.gov/snp/4257918) within CPVL; [rs2251375](https://www.ncbi.nlm.nih.gov/snp/2251375) within H19; [rs1546570](https://www.ncbi.nlm.nih.gov/snp/1546570) within DIS3L (Appendix 3, Supplemental Table S1). SNPs were annotated using wANNOVAR (see Appendix 3).

### Analysis model. {#sec2-1-4}

COPD was defined as forced expiratory volume in 1 s/forced vital capacity (FEV~1~/FVC) \<0.7, while controls had FEV~1~/FVC \> 0.7. In a secondary analysis, moderate-to-severe COPD cases were defined as FEV~1~/FVC \< 0.7 and FEV~1~ \< 80% predicted. Student's *t*-tests between controls and COPD were used to identify differences in *k* (positively dependent upon muscle oxidative capacity) or habitual physical activity from number of steps/day. Linear regression with an additive genetic model was performed to identify association of *k* with each of the 11 SNPs, adjusting for age, weight, FEV~1~% predicted, steps/day, and principal components of genetic ancestry using PLINK2.0. Stratified models in moderate-to-severe COPD cases and controls were also evaluated for association with *k*. NHW and AA individuals were analyzed separately; results were then combined in a fixed-effects meta-analysis in METAL, resulting in a total sample size of 152 in the fully adjusted model. Bonferroni-corrected significance was accepted at *P* \< 0.0045, and nominal significance was defined as *P* \< 0.05.

RESULTS {#sec3}
=======

COPD patients had lower muscle *k* than controls (mean ± SD in all COPD vs controls, 1.26 ± 0.37 min^−1^ vs. 1.60 ± 0.44 min^−1^, *P* \< 0.0001). Steps/day did not differ between COPD and controls (5,740 ± 4,726 vs. 6,509 ± 3,294; *P* = 0.24) (Appendix 1, Supplemental Fig. S2).

No SNPs were significantly associated with *k* in meta-analysis (Appendix 2, Supplemental Table S3). [rs2792022](https://www.ncbi.nlm.nih.gov/snp/2792022) within *BTAF1* \[effect allele frequency (EAF) = 0.819, β = 0.130, *P* = 0.053\] and rs24575771 within *SLC22A3* (EAF = 0.352, β = 0.106, *P* = 0.058) tended toward nominal significance. Subsequent analysis, stratified by disease state, identified three SNPs nominally associated with *k* in moderate-to-severe COPD only ([rs6481619](https://www.ncbi.nlm.nih.gov/snp/6481619) within *SVIL*, EAF = 0.746, β = 0.152, *P* = 0.013; *BTAF1*, EAF = 0.798, β = 0.196, *P* = 0.046, I^2^ = 41.6; Het\_*P* = 0.191; [rs7386139](https://www.ncbi.nlm.nih.gov/snp/7386139) within *DEPTOR*, EAF = 0.219, β = 0.159, *P* = 0.047; Appendix 2, Supplemental Tables S4 and S5). Forest plots stratified by genetic ancestry and disease state are in Appendix 3, Supplemental Figures S1--S3. Two other SNPs tended toward nominal significance in COPD (*P* \< 0.1; Appendix 2, Supplemental Table S5). Results of all models stratified by genetic ancestry are in Appendix 3, Supplemental Tables S2--S4.

INTERPRETATION {#sec4}
==============

This study of 152 smokers is the first to associate SNPs \[from candidates identified by Timmons et al. ([@B5])\] with muscle oxidative capacity in humans. Nominal association of *k* in moderate-to-severe COPD patients with a SNP intrinsic to *DEPTOR* is of particular interest as this gene is involved with molecular, metabolic, and contractile properties characteristic of glycolytic muscle. As our models adjusted for pulmonary function (FEV~1~) and physical activity (daily steps), the finding of nominally associated SNPs with *k* in moderate-to-severe COPD subjects only, and not in controls, suggests an interaction of these variants with some as-yet-unidentified aspect of COPD. Validation of these candidates may identify new risk factors for symptoms and/or poor outcomes in COPD and other lung diseases where peripheral deconditioning and low muscle oxidative capacity contributes significantly to disease burden. Given that pulmonary rehabilitation is the most beneficial treatment for severe COPD, these SNPs may provide a means of personalizing COPD therapy. These data strengthen the rationale for a larger study to identify potential contributions of genetic variants to low muscle oxidative capacity in COPD patients.
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